Literature DB >> 12603418

Preoperative urodynamic and symptom evaluation of patients undergoing transurethral prostatectomy: analysis of variables relevant for outcome.

O W Hakenberg1, C B Pinnock, V R Marshall.   

Abstract

OBJECTIVE: To assess the value of preoperative symptom score assessment and pressure-flow measurement in men undergoing transurethral prostatectomy (TURP). PATIENTS AND METHODS: In a prospective study, 95 men (mean age 74.3 years) scheduled for TURP because of their lower urinary tract symptoms, flow rates and urinary residual volumes were assessed using the self-administered International Prostate Symptom Score (IPSS) and urodynamic pressure-flow studies. At 3 months after TURP the patients were reassessed with a flow rate measurement and the IPSS. The baseline IPSS and urodynamic values were analysed with respect to the endpoints of the study, flow rate and IPSS after TURP, and the improvements thereof, respectively.
RESULTS: There were significant improvements in mean IPSS (- 10.87 points) and peak flow rate (+ 7.06 mL/s) 3 months after TURP. Classifying the patients into subgroups with distinctly different initial values for IPSS, flow rate, residual urine volume and degree of obstruction (as expressed by Abrams-Griffiths number) showed that the flow rate and degree of obstruction influenced the improvement in flow rate but not in symptoms after TURP. Symptom improvement was only related to the initial level of symptoms. In a multivariate analysis, only age was an independent predictor of the outcome variables of flow rate and symptoms.
CONCLUSIONS: Clinical decision-making remains a valid instrument for selecting patients for TURP. Both the IPSS and pressure-flow assessment are useful to exclude patients who are unlikely to benefit from TURP. Age is an important predictor of the improvement in symptoms and flow rates after TURP for the lower urinary tract symptom complex associated with benign prostatic enlargement.

Entities:  

Mesh:

Year:  2003        PMID: 12603418     DOI: 10.1046/j.1464-410x.2003.04078.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  7 in total

1.  Urinary retention presenting as complete bowel obstruction.

Authors:  Dino Papeš; Silvio Altarac; Nuhi Arslani; Zoran Rajković
Journal:  Can Urol Assoc J       Date:  2013 Sep-Oct       Impact factor: 1.862

2.  Change in storage symptoms following laser prostatectomy: comparison between photoselective vaporization of the prostate (PVP) and holmium laser enucleation of the prostate (HoLEP).

Authors:  Min Chul Cho; Seung Beom Ha; Seung-June Oh; Soo Woong Kim; Jae-Seung Paick
Journal:  World J Urol       Date:  2014-11-07       Impact factor: 4.226

Review 3.  Urodynamics: what to do and when is it clinically necessary?

Authors:  Matthew P Rutman; Jerry G Blaivas
Journal:  Curr Urol Rep       Date:  2007-07       Impact factor: 3.092

4.  Factors affecting the improvement of the initial peak urinary flow rate after transurethral resection of the prostate or photoselective vaporization of the prostate for treating benign prostatic hyperplasia.

Authors:  Hwa Sub Choi; Dong Jun Kim; Dong Suk Kim; Kyoung Pil Jeon; Tae Yoong Jeong
Journal:  Int Neurourol J       Date:  2011-03-30       Impact factor: 2.835

Review 5.  Diagnostic value of urodynamic bladder outlet obstruction to select patients for transurethral surgery of the prostate: Systematic review and meta-analysis.

Authors:  Myong Kim; Chang Wook Jeong; Seung-June Oh
Journal:  PLoS One       Date:  2017-02-27       Impact factor: 3.240

6.  Is Prostate Urethral Lift Effective in Patients with Multiple Comorbidities?

Authors:  Sun-Tae Ahn; Dong-Hyun Lee; Sun-Bum Cho; Hyun-Soo Lee; Da-Eun Han; Tae-Yong Park; Du-Geon Moon
Journal:  J Clin Med       Date:  2022-03-30       Impact factor: 4.241

Review 7.  A new algorithm in patients with elevated and/or rising prostate-specific antigen level, minor lower urinary tract symptoms, and negative multisite prostate biopsies.

Authors:  Koenraad van Renterghem; Gommert Van Koeveringe; Ruth Achten; Philip van Kerrebroeck
Journal:  Int Urol Nephrol       Date:  2009-06-03       Impact factor: 2.370

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.